RecruitingGastric CancerGastroesophageal Junction CancerBiliary Tract Cancer
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Eligible age
18+ yrs
Accepts
All genders
Locations
5 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Sponsor: AstraZeneca
Where it's recruiting
California
Orange · Palo Alto · Santa Rosa
Kentucky
Louisville
New York
Commack
Rhode Island
Providence
Texas
Houston
Source: ClinicalTrials.gov · NCT06219941 · last updated 2026-09-30